WO2004022104A3 - Foxp2 and uses thereof - Google Patents

Foxp2 and uses thereof Download PDF

Info

Publication number
WO2004022104A3
WO2004022104A3 PCT/GB2003/003884 GB0303884W WO2004022104A3 WO 2004022104 A3 WO2004022104 A3 WO 2004022104A3 GB 0303884 W GB0303884 W GB 0303884W WO 2004022104 A3 WO2004022104 A3 WO 2004022104A3
Authority
WO
WIPO (PCT)
Prior art keywords
foxp2
protein
patient
treating
expression
Prior art date
Application number
PCT/GB2003/003884
Other languages
French (fr)
Other versions
WO2004022104A2 (en
Inventor
Alison Hilary Banham
Philip James Brown
Simon Edward Fisher
Original Assignee
Isis Innovation
Alison Hilary Banham
Philip James Brown
Simon Edward Fisher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Alison Hilary Banham, Philip James Brown, Simon Edward Fisher filed Critical Isis Innovation
Priority to AU2003263329A priority Critical patent/AU2003263329A1/en
Publication of WO2004022104A2 publication Critical patent/WO2004022104A2/en
Publication of WO2004022104A3 publication Critical patent/WO2004022104A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present invention relates to FOXP2 and in particular to the use of FOXP2 in treating or identifying patients with cancer. More particularly the invention discloses a method of treating a disorder in a patient characterised by reduced expression of FOXP2 protein, which method comprises, administering to a patient in need thereof a therapeutic amount of any of a nucleic acid molecule encoding said FOXP2 protein, FOXP2 protein or a composition capable of stimulating an increase in FOXP2 protein expression in the tissues of said patient. Also covered by the application are further methods, compositions, vectors, kits and assays relating to FOXP2.
PCT/GB2003/003884 2002-09-06 2003-09-08 Foxp2 and uses thereof WO2004022104A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003263329A AU2003263329A1 (en) 2002-09-06 2003-09-08 Foxp2 and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0220776A GB0220776D0 (en) 2002-09-06 2002-09-06 FOXP2 and uses thereof
GB0220776.9 2002-09-06

Publications (2)

Publication Number Publication Date
WO2004022104A2 WO2004022104A2 (en) 2004-03-18
WO2004022104A3 true WO2004022104A3 (en) 2004-07-29

Family

ID=9943642

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/003884 WO2004022104A2 (en) 2002-09-06 2003-09-08 Foxp2 and uses thereof

Country Status (3)

Country Link
AU (1) AU2003263329A1 (en)
GB (1) GB0220776D0 (en)
WO (1) WO2004022104A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060025338A1 (en) * 2004-03-08 2006-02-02 Ludwig Institute For Cancer Research Compositions and methods for treatment of lymphatic and venous vessel arterialization
US8158596B2 (en) 2007-05-11 2012-04-17 The Regents Of The University Of Michigan Materials and methods for FOXP3 tumor suppression
GB0823020D0 (en) 2008-12-17 2009-01-28 Isis Innovation Use of FOXP2 as a marker for abnormal lymphocytes and as a target for therapy of disorders associated with abnormal lymphocytes
US9631194B2 (en) 2014-04-04 2017-04-25 Beth Israel Deaconess Medical Center Methods and compositions for use in treatment of FOXP2-related cancers

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
LAI CECILIA S L ET AL: "A forkhead-domain gene is mutated in a severe speech and language disorder", NATURE (LONDON), vol. 413, no. 6855, 4 October 2001 (2001-10-04), pages 519 - 523, XP002270201, ISSN: 0028-0836 *
PINKER S: "Talk of genetics and vice versa.", NATURE. ENGLAND 4 OCT 2001, vol. 413, no. 6855, 4 October 2001 (2001-10-04), pages 465 - 466, XP002270200, ISSN: 0028-0836 *
SHU WEIGUO ET AL: "Characterization of a new subfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 29, 20 July 2001 (2001-07-20), pages 27488 - 27497, XP002264690, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2004022104A2 (en) 2004-03-18
AU2003263329A1 (en) 2004-03-29
GB0220776D0 (en) 2002-10-16

Similar Documents

Publication Publication Date Title
DE60028970D1 (en) AT HER2 BINDING PEPTIDE COMPOUNDS
WO2003059951A3 (en) Novel anti-igf-ir antibodies and uses thereof
WO2004092405A3 (en) Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
EP2292664A3 (en) Multispecific deimmunized CD3-binders
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
WO2002083945A3 (en) Diagnosis and treatment of cancer: i
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
CY1114679T1 (en) COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DISEASES COMBINED WITH SURFACE EXPRESSION OF RUTINS
AU2003205077A1 (en) Imaging agents and methods of imaging naaladase of psma
WO2006034373A3 (en) Variants and chemically-modified variants of phenylalanine ammonia-lyase
WO2004098377A3 (en) Methods and compositions for diagnosis and therapy of parkin-associated disorders
WO2005100998A3 (en) Membrane markers for use in cancer diagnosis and therapy
WO2005112981A3 (en) Compositions and methods for the stimulation or enhancement of bone formation and the self-renewal of cells
NO20055209D0 (en) Peptabody for cancer treatment
WO2004019893A3 (en) Modulators of angiogenesis
WO2003102185A3 (en) Methods and compositions for treating neoplasia relating to hnrnp a1 and a2 nucleic acid molecules
WO2002101071A3 (en) Cd43:modulators of mast cell degranulation
WO2004022104A3 (en) Foxp2 and uses thereof
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2003012055A3 (en) Sak: modulation of cellular proliferation for treatment of cancer
WO2005110460A3 (en) Diagnosis and treatment methods related to aging, especially in muscle (14.1)
AU2002325328A1 (en) Asthma-associated gene
WO2007134907A3 (en) Gm-csf gene therapy for treatment of crohn's disease using an improved regulated expression system
WO2003020294A8 (en) Aromatase marking

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP